AUS
NZ
UK
CA
USA
IND
Highlights
- FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.
- Phase 2 trial results show promising response rates for avutometinib and defactinib.
- First potential FDA-approved treatment specifically for KRAS mutant LGSOC patients.
Verastem Oncology (NASDAQ:VSTM) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the combination of avutometinib and defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The FDA has granted Priority Review status to the NDA, which was submitted in October 2024, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 30, 2025.
This breakthrough combination therapy, if approved, would represent the first FDA-approved treatment specifically for adults with recurrent KRAS mutant LGSOC, a form of ovarian cancer that is difficult to treat and often has a poor prognosis. The submission is based on the promising results from the Phase 2 RAMP 201 clinical trial, which demonstrated substantial overall response rates and durable responses in patients. These results suggest that the combination of avutometinib, a selective MEK inhibitor, and defactinib, a focal adhesion kinase (FAK) inhibitor, could provide significant benefit to a patient population with limited therapeutic options.
The FDA’s decision to grant Priority Review underscores the potential for this combination therapy to offer a significant improvement over current treatments for recurrent KRAS mutant LGSOC. The Priority Review designation typically indicates that the FDA believes the drug may offer a meaningful therapeutic advantage over existing options, allowing for a faster review process and potentially quicker access for patients.
While the FDA’s acceptance of the NDA is a significant milestone for Verastem, the approval is not yet guaranteed. The company is also conducting the ongoing Phase 3 RAMP 301 confirmatory trial, which aims to provide further clinical data to support the expanded use of the combination therapy, potentially extending its indication to include patients with LGSOC regardless of KRAS mutation status. However, the trial is still ongoing, and its results may impact the final approval decision.
The fact that the FDA is not planning an advisory committee meeting for this application could potentially streamline the approval process, reducing the time it takes to reach a final decision. This is a positive sign, as advisory committee meetings are often held when there are significant concerns or uncertainties about a drug's efficacy or safety.
Despite the promising developments, there are still uncertainties surrounding the final outcome. FDA approval remains pending and is not guaranteed, and the results of the Phase 3 RAMP 301 trial could influence both the scope of the indication and the overall regulatory pathway. Additionally, the ongoing clinical trial will likely provide more clarity regarding the long-term efficacy and safety of the combination therapy.
In conclusion, Verastem Oncology’s NDA acceptance and Priority Review for the combination of avutometinib and defactinib in KRAS mutant recurrent LGSOC is a significant step forward in the treatment of this challenging cancer. If approved, it would offer a new treatment option for patients with few alternatives, marking a major achievement for both the company and the broader oncology community. However, as the final approval decision and Phase 3 trial results are still pending, the outlook remains uncertain for the therapy’s eventual availability.
